Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Xvivo, Audiocast, Q2'26

By Inderes7/14/2026, 12:00 PM
Xvivo Perfusion

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Christoffer Rosenblad
00:00 - 15:20

Thank you so much. Good morning and good afternoon, everyone, and welcome to the XVIVO Perfusion AB earnings call for the second quarter of 2026. To get started, we go to slide two. Today's presenters are me, Christoffer Rosenblad, CEO, calling in from Gothenburg, Sweden, and Kristoffer Nordström, CFO, calling in from Denver, Colorado. And with that, we can go over to slide three, which is the Q2 financials at a glance. The Q2 results show sales amounts in line with the previous quarter, Q1, and with a 36% organic top line growth compared to the same quarter last year. EBITDA was kept at a healthy level, resulting in a good operating cash flow for the third consecutive quarter. The total cash flow was neutral and hence the cash position is stable, Kristoffer Nordström. Our CFO will get into the details on sales, gross margin, cash flow, and EBITDA later in this presentation. If we look into the segments, both the thoracic and abdominal segments are growing rapidly in both regions. North America and Europe. The lung market trend from Q4 last year continued into 2026 with good market growth. I am also very pleased with the strong kidney sales in the quarter, fueled by a larger sales footprint in Europe and a growing sales force, and most importantly, growing interest from clinicians in the United States. We will come back later in the presentation to the progress of the services segment, the actions taken, and how we will execute to become the preferred partner in the transplant process. And with that, we can go over to the next slide, which is slide number four, which shows the same picture but for the first six months of the year. It shows a similar picture to the quarter. Good, stable overall growth comes from strong thoracic growth and healthy abdominal growth. During this year, we have continued to invest mainly in sales force, scalable production structures, as well as regulatory approval. Sales came in at 480 million Swedish kronor with a 29% organic growth. If we look into the segments, we can see that for heart, the main hurdle is regulatory approval. Once the Heart Assist is used, the feedback is overwhelmingly positive. We continue to build evidence, and more than 600 patients now have been successfully transplanted with Heart Assist. The best testament to success is Australia, where the heart penetration year one was approximately 30%, and year two, it increased to 40% of hearts in 2025. This year, we already see an increase to approximately 50% penetration of all transplanted hearts in Australia. I also want to mention that our projects are progressing according to plan. Regulatory timelines are hard to predict, but clinical trial submission files and development progress are advancing according to timelines. We have previously agreed internally that the full-scale production of disposables for heart, liver, and kidney will be extremely important to capture future growth potential for all three products. With that project coming to an end, we will now focus on reducing cost per disposable, setting up dual production where deemed necessary, as well as improving our machine production setup. This project will also include our lung portfolio. Lastly, and most importantly to mention, is that this quarter again shows that the business model is scalable. So we increased sales. We see that turning into an improved EBITDA and an improved underlying cash flow. So with that, we can go over to slide five, and we will come back later to the financial numbers in that section. And we can go into the Q2 highlights on slide five. Those we will see on slides six and seven. So we can go straight to slide six. One key is that we definitely start to see that with a larger sales force, we meet more customers and we see an increase in adoption of our technologies across the line. Number two, we mentioned before that the lung market is back, and we are playing a very important role in running an EVLP hub pilot that is now successfully up and running. And that explains partly the increased lung sales during the quarter. So far, the progress is in line with the plan, and we have identified 4 to 5 EVLP hubs in the rollout pipeline, whereof the third hub was onboarded last week. We are continuously investing in more feet on the ground in the US to enable closer customer relations with the growing number of EVLP partners. If we look at segment three. Let us look into our heart segment. As I just stated, in Australia, we saw fast pickup of usage early on and it increases year by year. Now we see a similar interest in Europe, and it is translated into usage under derogation or compassionate use. It is interesting. We hear more and more testimonials from customers who say that the Heart Assist Transport has changed, not only the ability to transplant more patients with a higher patient survival rate, but it also reduces stress levels in the transplant team and increases the confidence in heart transplantation in the US. The interest in our Ex-vivo heart technology is equally high, and we have recently submitted the extension of the CAP or Continuous Access Protocol to the FDA. As I mentioned in the last quarterly call, I will mention again that after spending time at the ISHLT 2026 in Toronto, it is clear that XVIVO is by far the innovation leader in the field of both lung and heart transplantation. If we look into number four, we saw increased sales from the Kidney Assist Transport, and we also see an increased interest and momentum from customers using the Kidney Assist Transport. This is based on more and more clinical evidence being available to the clinicians that support the use of Kidney Assist Transport, as well as a larger commercial footprint in both regions, Europe and the US. In parallel, we are working hard to develop the product to meet US market needs, as well as lowering the cost per disposable to increase margins over time. And with that, we continue on highlights and slide number seven. Point five. What is very encouraging is to see that where we put commercial capabilities and increase our sales force, we grow typically between 30% and 60%. And with future approvals expected and coming in, as well as our product improvements, we will continue to see this leverage of our commercial sales force turning into increased sales at a good return on investment. Even though I wish to have point six here, we have seen great progress in all our regulatory processes as we have worked hard on the derogation and compassionate use programs here in Europe. We see the uptake in Australia, and now we see that we have what I deem as good progress in the regulatory processes. I will shed more light on where we are on each approval. In the next section of the call, I will provide the regulatory and clinical update. But I just want to conclude here that we are pleased with what we have seen so far. If we look at point seven, a very important point to start with, we are very pleased with the growth and the cash flow we saw during the first half of the year. We continue to invest heavily in future growth. The majority of the investment, of course, goes into regulatory applications for heart globally and liver in the US. But besides that, we continue to invest heavily in building commercial capability and the production scale-up to enable higher volumes than we have today. We are also investing in quality capabilities to support the growth we will see, which we believe will be tenfold in volume versus what we see today. And lastly, number eight, that captures, I think, the first half of the year: we have a scalable business model. We do invest to capture that opportunity and we see increased sales. Turning to EBITDA, that turned into an improved operating cash flow that we can then invest into. Regulatory approvals of our future sales drivers, which are heart global and liver in the United States. And with that nice segue, we can go into the regulatory update, slide number eight. But we can actually quickly go to slide number nine to go through the regulatory processes we have. This is the usual overview that we show every quarter on slide nine. We now see more and more evidence for heart technology globally. In Europe, we saw the first randomized control trial with superior endpoints performed in the field of heart transplantation. The clinical outcome was great with an additional six lives saved per approximately 100 patients. It is also the first clinical trial to establish a link between preservation method, severe PGD reduction, and reduced one-year mortality. In the analysis of the trial, it was noted that the group had a reduction of severe PGD by 76%, which is a large comparable number, as severe PGD was 20% in the control group, which is expected, but only 5% in the XVIVO group. It was further noted that the mortality of the severe PGD was approximately 40% in both groups, leading to an increased survival of six percentage points in the XVIVO group versus the control group. The US heart trial was fully enrolled in record time. It showed the same picture. The severe PGD rate there was only 7.9%. We are now finalizing the submission for the FDA for their review. So the team is working very hard. We are expected to hand in the submission file to the FDA during this quarter. After that, we are waiting for some validation and publication data before we can finally submit it. In Europe, the CE marking process is ongoing and is at a late stage in my best judgment. As stated earlier, the Heart Assist and disposable part of the product are already CE marked. The solution has passed EMA consultation and we are now waiting for consultation at the submitting agency for the one part of the product. During Q2, we received a few questions of a clarification nature, which we turned around in less than a week. We are now waiting for feedback on that additional information, where we unfortunately don't have an exact timeline, but we expect feedback during this quarter. Q3, as we stated earlier, the uptake of Heart Assist is good in Europe under derogation and compassionate use, and we are ready to launch when the product is fully approved. Hence, the launch plan is ready. We have staff recruited and they are meeting customers today. Under derogation to support them with everything they need. And the interest from clinics is very high in Europe as it is in the rest of the world. I still want to mention that even though the use under derogation and compassionate use is increasing and appreciated by our customers, we need to mention that the European heart clinics are suffering badly from the lack of alternatives to the Heart Assist. In both the United States and Canada, regulatory approval will be pending the CE marking in Europe. So we are waiting for that before we seek approval in those two regions. The last point. Liver in the United States. I will come back with an update on the next slide. Slide 10 and the Liver Assist regulatory status in the United States. So we have previously reported that the Liver Assist has been granted breakthrough device designation by the FDA with an approved IDE and CMS funding approved. We could have started a trial in Q3 already last year; at this point, pretty much one year ago, we did decide to temporarily pause activities for the liver PMA process to investigate alternative regulatory routes. We are preparing for the FDA Q-sub meeting where the possible regulatory route will be decided by the FDA. We have recently opted to focus the majority of the resources we have on the heart US submission. That being said, we have very high interest from US clinics that are supporting the US Liver Assist submission. And we. We are in good dialogue with clinics to prepare ourselves for the Q-sub meeting with the FDA. We will inform all investors of the next steps in the US regulatory investigation. Latest in the Q3 report. We will inform all investors of the next steps in the US regulatory investigation, either in the Q3 report or earlier if we deem it necessary. And with that, I conclude the first section of the Q2 presentation. And I will hand over to our CFO, Kristoffer Nordström, who will present the financial performance.

Kristoffer Nordström
15:22 - 23:42

Yes. Thank you. Christoffer. Turning to the financial performance for the second quarter. So, this was another strong quarter for XVIVO. The strong momentum we saw in the first quarter continued into Q2, as you have seen, and we delivered net sales of 239 million SEK, which corresponds to an organic growth of 36% in local currencies. Importantly, growth was broad-based across our portfolio and driven by continued adoption of our technologies in all major regions. We are pleased to see that. At the same time, we continue to invest in commercial capabilities, regulatory activities, and operational scale-up initiatives while maintaining a solid profitability. EBITDA amounted to 45 million SEK, and that is around 19% in EBITDA margin. And we believe that this demonstrates both the strength and the scalability of our business model. I will get back to that. Gross margin was 71%. Thoracic margins remain strong, while gross margins in Abdominal and services continue to impact the overall mix. I will come back to that as well. In a moment, we will go over to the next slide, which is the largest business area. Today, let's turn to XVIVO Thoracic. So Thoracic delivered a positive quarter with net sales of 158 million SEK and an organic growth of 53%. Adjusted for the heart trial, revenue was still at 52% organic growth, which is very good. The momentum in lung continued to strengthen. EVLP disposable sales grew 69% in the quarter, and we continue to see expansion beyond our largest customer accounts. Activity remains strong both among leading transplant centers, but also within our growing abdominal strategy during the quarter. As an example, two additional X-ray systems were installed at OPO's in the United States and are expected to become operational in the second half of the year. Heart. Christoffer touched upon it. We are very pleased and proud to see that we delivered a particularly strong quarter in heart, generating sales of 24 million SEK, primarily from Europe and Australia. We continue to see increasing use under compassionate use and derogation while we wait for our regulatory approvals. With the approximately 600 heart transplants with our technology, we continue to build both clinical experience and commercial momentum ahead of our future approvals, which will be very important. Gross margin for Thoracic was 83%, remaining at a very attractive level despite the increasing contribution from heart sales, which we should remember is still at pre-launch pricing. Moving over to Abdominal, Abdominal delivered another strong quarter and reported net sales of 65 million SEK, corresponding to 26% organic growth. Liver sales grew 11% in local currencies, while kidney contributed and was the primary growth driver with a growth of 72%. So we are particularly encouraged by the continued adoption of Kidney Assist Transport both in Europe and North America. As more centers gain experience with the early adoption of this technology. Gross margin was 57%. So an improvement from Q1, but less than the 68% seen last year. The decrease was primarily driven by product mix with kidney representing a larger share of sales as well as pricing conditions in certain markets. While this impacts margins in the short term, we remain very confident in the long-term margin opportunity within Abdominal as adoption increases in the US, where pricing levels are structurally higher. And as we continue implementing manufacturing and sourcing improvements, we expect margins to improve over time. So overall, we remain satisfied with the growth trajectory in Abdominal and the increasing adoption of both our liver and kidney technologies. Turning to services. Our third business area net sales were 15 million SEK, corresponding to negative growth of 25%. The development continues to be explained mainly by lower organ recovery volumes, while Flowhawk delivers another strong quarter. Flowhawk grew 48% organically and continues to gain traction among transplant programs across the United States, and we remain convinced that the digital workflow solutions will become an increasingly important part of transplant infrastructure and customer integration for XVIVO over time. Within organ recovery, volumes remain below our expectations. Yet another quarter. However, following the investments we have made into the organization and the talent that we have attracted, we feel that we are getting closer to growing our customer base. We have a firm focus on returning to growth here in the second half of the year. I think we should see some results, especially in the second half of the year. Gross margin was 10%. And that is purely reflecting the lower organ recovery volumes combined with our investments in capacity. As volumes recover, the margins should naturally improve. So switching gears from sales and going into EBITDA and profitability. Despite continued investments, as we talk a lot about in commercial expansion, regulatory activities, and scaling the organization for future growth. EBITDA remains strong at 19% in the quarter and 20% year to date, and on a rolling 12-month basis, our EBITDA has now improved to 21%. Many companies can deliver high growth, and many companies can deliver profitability. And we believe that delivering 29% organic growth during the first half of the year, while sustaining around 20% EBITDA margins and generating positive cash flow, demonstrates the quality of our business model. And this is already at a very early phase of our growth journey. So we are very proud of that. As we have said previously, XVIVO's business model is highly scalable. We will continue to invest where we see clear long-term commercial opportunities, particularly in North America and the US. But we will also maintain disciplined cost control across the organization. My final slide. Cash flow. One of the most encouraging aspects of the quarter, we think, was the continued improvement in cash generation. Operating cash flow amounted to 63 million SEK in the quarter and 129 million SEK year to date. And this should be compared with a negative operating cash flow during the first half of the year last year. So this reflects both the stronger commercial performance and the continued focus on working capital management. Cash flow from investments amounted to -68 million SEK in the quarter and relates primarily to regulatory and product development activities, especially within heart. What we think is particularly important is that over the past three quarters, we have demonstrated our ability to largely self-fund both our operating investments and our growth investments, our CAPEX. So despite continued investments into future growth, total cash flow for the first half of the year was essentially break even. And we ended the quarter with a strong cash position of 305 million SEK. So with those comments, I will hand it over to you again. Thank you.

Christoffer Rosenblad
23:46 - 27:47

Thank you, Kristoffer Nordström. We will round off this presentation with the outlook for the rest of the year and then a longer-term outlook. We start with slide. 19 and the outlook for 2026 and our focus areas. So we will continue to build our sales force and build new partnerships in the US to enable OPO and other clinics to recover more lungs by EVLP adoption through a combination of service models and staying very close to customers. In parallel, we are increasing our service offering to better tailor to customer needs, especially by offering Flowhawk and NRP from a hopefully increased footprint. We have an increased surgical footprint. We should also have an increased contract footprint. And we will continue to work closely with our competent authorities in Europe with the aim of obtaining the CE marking for heart. Of course, we are aiming to submit the regulatory heart file to the FDA for their review during this quarter, as well as deciding the regulatory pathway for Liver Assist in the United States, with the aim of giving surgeons the same opportunity we now see here in Europe using the Liver Assist, where European clinical teams save hundreds of lives every quarter. Thanks to Liver Assist. And if we turn from this year's outlook to a slightly longer-term view, which I think is important to keep in mind, the demand for transplants is still ten times higher than the supply of organs. We should also remember that the sales value for machine perfusion is approximately ten times higher versus what is used today to a large extent, static cold storage or a beer cooler box type with ice. Machine perfusion and our service models have proven to increase the number of organs to be used for transplantation, especially in the fast-growing DCD organ pool. Where the main growth drivers are superior clinical results from machine perfusion and the fact that we can reduce complexity and add time for the transplant clinic in order to reduce stress. So, in conclusion, we know that machine perfusion and good service models are the new normal. And DCD graft will drive growth in the near and the long-term future. Lastly, we want to change the paradigm for transplantation by innovation. We are convinced and committed to increasing patient lives after transplantation, making sure that no one dies waiting for an organ, and making sure that we have rested transplant teams performing surgery at a lower cost than what we see today in the transplant chain. And we hope that you, dear listener, in the future, when you fly, you might be seated near to an XVIVO Heart Assist Transport box with a heart being transported to a patient whose life is about to change soon. And if you see that device on your flight, you should know that it is not just a heart traveling. It is a hope for a new and a better life for the patient and his or her family. And I want to thank you for supporting us on this journey to change the transplant system forever through superior innovation. And with those last words, I also want to thank you for listening today. And with that, we will open up the lines for questions.

Operator
27:48 - 28:06

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Simon Larsen from Danske Bank. Please go ahead.

Simon Larsen
28:09 - 28:45

Yeah. Good afternoon, everyone. A few questions from me, and I would like to start on the strong heart segment growth that you mentioned. Would it be fair to assume that sales in this quarter were potentially boosted by a high number of new box placements, or were revenues mainly stemming from existing clients already using consumables? And how should we think about the basic run rate for the business, or the dynamics of the business model here at the beginning of the launch, and should we extrapolate anything into the second half?

Christoffer Rosenblad
28:47 - 29:21

Thank you. Simon. It is a great question. We are scaling up in Europe. There were limited Heart Assist Transport box sales both in Q1 and Q2. So, the main sales are coming from disposables. But we should remember that once you get started, you have a few kits, a safety stock. So that has affected the first half of the year to some extent. But we definitely see increasing uptake in Europe from existing users.

Simon Larsen
29:24 - 29:56

Great. And the second question was on EVLP. So I believe you have three APOs. Uh, yeah. Signed now soon, online as well. It sounds like there are more in the pipeline, hopefully for the remainder of the year. So, if you could help us understand the potential of these Apos when it comes to revenue, I assume you have data on their current volumes and growth rates. . So I am just trying to understand what 3 to 5 APOs can do for you in, let's say, the next fiscal year. What is the magnitude we are talking about?

Christoffer Rosenblad
29:58 - 30:53

We are in the pilot phase. So we need to come back in probably six months to answer that question properly and with more exact data. But what we do see is that the opportunity to evaluate the lungs on the research side vastly outnumbers the opportunity on the clinical side due to their access to extended criteria lungs. That is there. And also the fact that it simplifies the whole process. And so we have seen in one region, we saw a fairly fast uptake. We need to replicate that three to four times more to come back with exact numbers coming into next year. But so far it looks good. And according to our own plans, it is at least according to those.

Simon Larsen
30:55 - 31:24

Okay. Okay. Makes sense. And the final one was on further investments in the sales force when we're approaching a heart launch both in Europe and in the US, right into next year. So could you give us any help or a ballpark estimate on how many more salespersons and support persons do you need to really cater to and meet the demand, and to make it a successful launch for the Heart Assist Transport product? So what is the magnitude of investments, basically, that we should expect here in the next year?

Christoffer Rosenblad
31:26 - 32:21

Yeah. In Europe, we have invested, but there will be additional investments. As more customers come on board, we need a larger field force, ranging from customer support and technical support to clinical support and sales representatives. So that is more of a scaling exercise in the US. We will start our scale-up process next year. We, depending a little bit on the timing, believe that we need approximately 10 to 13 extra commercial headcounts, ranging from sales reps to customer support, technical support, and increased clinical training and support.

Simon Larsen
32:24 - 32:28

Okay. Okay, that sounds fair. Uh, thank you so much. I will get back in line.

Christoffer Rosenblad
32:28 - 32:29

Thank you.

Operator
32:32 - 32:36

The next question comes from Jakub Lemke from SEB. Please go ahead.

Simon Larsen
32:39 - 32:40

Yes. Hi.

Jakub Lemke
32:40 - 32:57

And good afternoon. My first question is on the customer channel. So I'm wondering about the first account that you won here earlier in the year, if you can elaborate on how that has developed and ramped up here in the first half of 2026?

Kristoffer Nordström
32:59 - 34:22

I can take that one. Yeah. So, you are right. We acquired that in the back end of last year, and they became active very early this year. And I would say they have a strong ambition at their site. It is a mutual ambition, volume-wise for EVLP, on par with the top five centers in the US. So we are talking about larger volumes. And this is a new method. And we are three parties that need to collaborate. So it is XVIVO and it is our perfusionist partner. And so there are learnings in the making. But we believe that we have a proof of concept to provide some more color. I think they are now close to, let's say, 20 EVLP procedures for the first half of the year. I know their ambition is higher than that when they are fully up and running. But we consider that a very strong start. And now we want to replicate that on the other accounts as well. I think you will see a variety of slightly lower volumes than this one, but also perhaps higher for other accounts as well. It is a good start.

Jakub Lemke
34:24 - 34:36

And this, let's say 20 in the first half. Is that a reasonable assumption for the second half of the year? Now is that a reasonable assumption for the second half of the year?

Kristoffer Nordström
34:36 - 34:58

Yeah. I think you will see that the ramp-up time could vary a little bit on these two deals. One is smaller and one is bigger. It is a little too early to say; I think a lesson is that it takes at least a quarter for them to come up to speed.

Jakub Lemke
35:01 - 35:12

Okay, that sounds fair. Then I have a question on the heart sales in Europe. Here in Q2, could you elaborate on what countries are contributing to that?

Kristoffer Nordström
35:15 - 35:50

Yeah. So we are very, very happy now with the footprint that we have in Europe. Naturally, there is some background noise here. I am not sure if it is you, but naturally these are sites that have participated in the European clinical trial. But we talk about France as we sent out a press release this year about the derogation. So they are contributors. You have the Benelux countries, Germany, Sweden and Denmark, if I remember correctly. So we think that is a very good starting point here. Um thank you.

Jakub Lemke
35:53 - 36:19

Okay. And then on the process for heart in Europe, I understand that it is very tough for you and it is hard for you to make predictions, but it sounds based on your commentary that we are unlikely to get this within the one-year horizon. Uh, yeah. Horizon from the press release sent out there. Yeah. August last year.

Christoffer Rosenblad
36:21 - 36:40

Yeah. Yeah. That is our best estimate at this moment. Based on where we are in the level of clarification, that being said, it is hard to predict regulatory timelines, especially during the summer, but yes, that is our best estimate.

Jakub Lemke
36:42 - 36:49

But it's still reasonable to expect it in 2026, perhaps.

Christoffer Rosenblad
36:50 - 36:52

Yes, I certainly hope so.

Jakub Lemke
36:55 - 37:09

Okay. I get it, it is tough. Then a question on liver, which had a bit slower growth here for the second quarter in a row. And I am wondering if there is something that has changed here or if it is only normal fluctuations.

Christoffer Rosenblad
37:12 - 38:11

I think that we had a fairly strong liver quarter last year. Uh. To start with. We have fairly strong comparables. We do have a good liver pipeline still in Europe. We believe that the majority of market penetration from here on will come from both increased sales in newer European countries where we have, for example, really high penetration in Benelux, as well as increased penetration in other countries. So Italy is a focus there. But we believe that a large part, besides new countries, will also come from improved service models here in Europe as well. If we look at the pipeline, it looks positive for liver as well.

Jakub Lemke
38:14 - 38:31

Okay. And just on liver, I know there is one competitor that is talking about expanding more into Europe. And there is another competitor that I know is growing a lot. You are not seeing any sort of increased competition from those in the short term.

Christoffer Rosenblad
38:33 - 39:32

We do see increased competition in Europe to some extent. Absolutely. But we believe we have a strong track record, very strong clinical proof, and good customer relations. So far, we have not seen that strong competition coming in. I believe that most of our success lies in our own hands and how effectively we implement good service models. When I talk to customers in liver, that applies to all organs, but especially they are looking for support in reimbursement, and particularly in service models due to the shortage of staff. So if we can support them with that, I am sure that we will become the preferred partner to a lot of clinics in Europe over time.

Jakub Lemke
39:35 - 39:36

Okay. That is all for me. Thank you.

Operator
39:40 - 39:45

The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.

Philip Wiberg
39:47 - 40:09

Hi. I have a couple of questions, but I will take them one by one. So the first one is around the largest customer that you have in lung. So you had another strong quarter here. So I am wondering what your expectations are now for the coming quarters and what kind of visibility you have there. And also, if your projections have changed at all following their own approval.

Christoffer Rosenblad
40:12 - 41:05

Thank you. In general, we stay close to all our customers, and especially the large ones. We are part of their approval. And we will continue to see increasing quantities. We are convinced of that. The sales value will of course be smaller compared to today. We have approximately six months of good visibility, and for that period, it looks good; after that, we have less visibility, so to speak. And we are in good dialogue to have a better understanding of how the future will be shaped together. So we need to come back on a more detailed answer to that question.

Philip Wiberg
41:06 - 41:26

Okay. Okay. Thanks. But I think in connection with the last report in Q1, you mentioned it was fair to assume that was a new baseline for the EVLP numbers. This seems to have been true in Q2. So, it sounds like you still have confidence around that statement now looking forward as well.

Christoffer Rosenblad
41:27 - 42:02

We are confident for the next six months. And we are also very confident that we together will increase the number of EVLP procedures so we can make sure that nobody dies waiting for a lung, and that is what we will do together. So we are convinced and committed to increasing the volume and the number of EVLP cases going forward. Exactly how that will shape up in US dollars is something we need to come back with. It is something we need to come back with. If we look into 2027, 2028, and 2029.

Philip Wiberg
42:05 - 42:34

That is all right. Thank you. And then a question on Heart as you now plan for the PMA submission after the summer. So now, how large would you say the uncertainty is around the exact timeline for that? Do you have all the clear steps that you need to take now going forward until that submission? And are you able to provide some more details around what that exactly is and what is remaining before you? You are ready for the submission.

Christoffer Rosenblad
42:35 - 43:53

The main hurdle or bottleneck is that we have had some changes of components with the product, which happens. So we need to verify all our product aging for the final product. So that is what we are waiting for now. During the summer. It is a large clinical file, a large product file, and an animal file as well. That needs to be a submission, but we have a great team on board. I sat with them for a week. The clinical results. Fantastic. I am confident that if nothing goes wrong, I am extremely confident. And then, with product aging or something out of our control, but if it comes to submission, I am writing the file, etc. I am 100% convinced that we will do that on time. Then it is more about the unknown unknowns, but for the rest, I am 100% confident that we will hit that timeline if nothing out of the ordinary happens.

Philip Wiberg
43:54 - 44:11

Okay. Very good. Lastly, from me regarding the CAPEX in the US, you submitted it, I think you said earlier. So how long does it take before the FDA can grant approval for that? And when can we expect transplants to start again in the US?

Christoffer Rosenblad
44:12 - 44:35

The short answer is that I do not know 100% for sure. But it is a fairly easy turnaround, so to say, for the FDA; to do my best guesstimate would be approximately 30 days turnaround time. Hence, it should be able to start somewhere here in Q3 if everything goes all right.

Philip Wiberg
44:37 - 44:40

Okay. Perfect. Thanks. That was all for me.

Operator
44:42 - 44:46

The next question comes from Ludwig, from Handelsbanken. Please go ahead.

Jakub Lemke
44:49 - 45:10

Thank you and good afternoon. I have two questions. I think I want to start by going back to what was discussed earlier regarding the investments in sales force. So when we think about OPEX and scalability going into next year, is the big driver of higher OPEX the investments in the sales force, or is there anything else we should also keep in mind?

Christoffer Rosenblad
45:12 - 46:53

That is a great question. Thank you for asking that one. With the growing company and growing machine fleet, you also need to scale up quality and technical product management. Let's say the back end of the company to take care of the growing fleet and be able to return answers to customers very fast. So there are, but those investments are limited in comparison to commercial capabilities. So that's why we normally talk more about commercial capabilities because that's where the bulk of investment will be funneled. Investment will be funneled. But you are right, there are in general, you also need to scale up the back end of the company in order to enable higher growth rates in terms of production. We don't see that we need to scale up because we are relying on the majority of third-party manufacturing. So that's more improvement projects, lowering costs over time, and efficient processes. We have the right people on board doing a fantastic job. So I don't see a large scale-up there, but definitely on the quality side. Take the product management side. There is a need, but compared to the commercial force, it is smaller and limited.

Jakub Lemke
46:55 - 47:01

And just to follow up on that. I mean, is it fair to expect that to grow in line with sales growth?

Christoffer Rosenblad
47:03 - 47:30

That should be in the beginning. It will be a larger investment, approximately six months before launch and 12 months after launch. But once that has stabilized, growth will far outpace those types of investments. It is more of an investment.

Jakub Lemke
47:30 - 47:57

Thank you for that. Yeah. Great. And then a question on Abdominal, I guess you mentioned in the report that you had some pricing conditions in, I believe, undisclosed markets. Could you elaborate a bit on this, if possible, to explain what kind of pricing conditions and what markets are affected? And is this for the entire Abdominal segment, or is it more towards liver or kidney?

Kristoffer Nordström
47:58 - 49:19

I can take that one. So, I mean, if you look at this, it relates to Europe primarily. But if you look at certain countries in Europe, you have Eastern Europe and certain South European countries where there simply is not enough money in the systems. Therefore, pricing has to be lower. It is at those countries and those markets where we do see competition from competitors implementing lower prices. And we will need to ask ourselves if those markets are at the moment attractive for us. If you look at the more important markets and what historically have been our main markets, you don't see that pricing pressure and you see an increased utilization, especially DCD and now looking into DCD as well. We see less competition today, but that might change. But I would say it is more that last year we were very successful in entering those markets, such as Eastern Europe and certain other countries. But it comes with lower margins, but that is not where you will see the growth for XVIVO Perfusion going forward. So I'm not worried from that perspective. It is just an effect we have at the moment.

Jakub Lemke
49:22 - 49:27

And just to be clear, was this something that you started seeing during Q2?

Kristoffer Nordström
49:28 - 50:23

No, the volumes in those markets have picked up for us during this year due to our successful installations of our devices last year. If you look at Q2 specifically, I would rather say it's the fact that we have been very successful in kidney, and kidney sales globally are at lower margins. That is how the market looks today. And with reimbursement long term, we hope that we can improve that. And also, we touched upon it. But I want to mention that one of the good outcomes of the manufacturing project that we have run now for two years, moving manufacturing from the Netherlands to Sweden, is that we will see a lower cost on, especially, our Abdominal portfolio. I would say perhaps not this year, but let's say starting from mid-next year, we should start to see that come in.

Jakub Lemke
50:27 - 50:53

Thank you. And then just a final question for me, please. Also on the COGS. I mean, besides what you just mentioned, you have also previously been speaking about kidney specific volumes being too low, which is why the gross margin has been lower. Besides the initiatives and the move of production that you mentioned, how much higher volumes do you think is needed to see higher gross margins for the kidney sales?

Christoffer Rosenblad
50:56 - 52:47

I can answer that to some extent. We need to see three things. One. One is a geography mix. I should also mention it is partly by choice where we choose to gather more data on kidney in countries with slightly lower margins, but you get very good data. It makes economic sense because we do not have to pay for it, so to say. But we pay for it through slightly lower margins. We think that will be very useful data going forward in approximately one to one and a half years. So it is a geography mix where when we grow more in high margin countries, it will, so to say, look like a better picture, then it is definitely a cost per kit. And there are two components there to look at. One is the component cost where we need to reduce that and also get a better process. And then lastly, we have seen that when we come up to stable production, it is not exactly a quantity issue because we do not have a pricing model with our production suppliers that is based on how much we purchase. So we do not get lower. If we purchase more, it is more that the process gets improved over time. And then year by year, you reduce costs due to improved processes and higher scale. So it is a combination of those three factors that I think will take one to one and a half years to get out of the system. But once we do that, we will have very healthy margins on our full product line.

Simon Larsen
52:50 - 52:50

Very clear.

Jakub Lemke
52:50 - 52:51

Thank you so much.

Operator
52:54 - 52:58

The next question comes from Ed Hall from Stifel. Please go ahead.

Ed Hall
53:00 - 53:25

Good afternoon. Thank you very much for taking my questions. I have a couple of questions here. The first one would just be on lung and the OCS. And I guess if we look into H2, to what extent do you view that as driving growth, and more specifically in Europe, regarding the EVLP momentum you have seen there, do you see that continuing through the rest of the year?

Christoffer Rosenblad
53:28 - 54:14

Yeah. Looking into the forecast. Yes. We believe that momentum will continue. We do see an increasing interest in lungs in general. EVLP in particular; the donor pool is becoming more and more extended criteria, to put it that way. Hence, there is a larger portion of DCD. There is more NRP being performed, which potentially harms the lungs, etc. . So there is an increased uncertainty coming from donor lungs. So we see an increased interest. And we believe that if we stay close to customers and do our job right, we believe that momentum will continue through the rest of the year. Yes. Both in Europe and the United States.

Ed Hall
54:16 - 54:39

Perfect. Perfect. That's really clear. And then maybe just more of a Q3 question, but obviously, we've seen the typical seasonality in the US for lung. And I was just wondering to hear your thoughts on it for this year, sort of given dynamics like phasing of revenues and obviously this growing, operating strength, is there anything to upset that seasonality?

Christoffer Rosenblad
54:43 - 55:34

I mean, in general, doing this for 14 years, Q3 typically has a bit of a weaker quarter, very much depending on the fact that it is when the majority of people take vacations. And that applies, of course, to transplant teams as well. Last year was a bit of an anomaly with an extremely weak Q2, and actually July and August. And then we saw volumes picking up in September, but that has more to do with the United States and the economy behind transplantation, specifically more resources in the transplant system. So if I look at a normal year, I would say Q3 is seasonally a bit weaker. And then from Q1 to Q2. Q4 is typically a little bit stronger.

Ed Hall
55:36 - 55:42

Okay. Perfect. So, this year, there's nothing to upset the last 14 years that you've experienced.

Christoffer Rosenblad
55:42 - 55:44

No, we haven't seen any sign of that so far.

Ed Hall
55:45 - 56:16

Okay. No, that's really clear. And then just my last question would obviously be on Flowhawk. And I appreciate it is a small part of your service business, but obviously it looks like it is growing really well and it is a SaaS. So I assume it has quite a high gross margin contribution. I just want to try and understand how big this could be in terms of your revenue and who is using it now? I'd just be curious to understand a little bit more about this business.

Kristoffer Nordström
56:18 - 57:39

Yeah, I agree with you. We have high hopes for Flowhawk, and it remains a very unique communication and transplant administration tool. We will paint this picture more deeply for you during the rest of the year as we move into our strategy work at XVIVO, but we see it as an air traffic control tower, more or less, that could be used by all transplant centers. And we believe that in the near future, you should be able to integrate our technologies with Flowhawk, which will create stickiness at the centers. And it can also potentially make us come even closer to the customers at the organ offering stage and so on. It is still very much in the early innings. That's why we're all so happy to see that we have this growth now. It comes from both renewals from happy customers, but also additional centers coming on board. So, it is definitely a product for the future for us.

Ed Hall
57:42 - 57:44

Perfect. That's really clear. Thanks a lot.

Christoffer Rosenblad
57:44 - 57:55

Thank you. I see we have one more question left. We are nearing the end of this call, but of course we will allow one more question. So, Elvin, please.

Operator
57:57 - 58:02

The next question comes from Elvin Roleder from DNB Markets. Please go ahead.

Elvin Roleder
58:03 - 58:48

Yes. Good afternoon. Thank you. I appreciate you taking the questions. Even though we're pretty much out of time, I will just have two questions and see if we can manage both, perhaps beginning with the gross margin dynamics in the Thoracic segment. They are strong, but they are still down a bit year over year. You mentioned mixed effects here in the quarter, and I guess it is because of the EVLP outgoing per FedEx year over year. But I also have a question regarding heart. So my question is, what is the current gross margin that you are operating with in the heart business and how would you expect this to evolve from where you are now to 12 months post-European approval? How should we think of that?

Christoffer Rosenblad
58:55 - 59:54

I can take that one. Yeah. Heart. Heart business, coming from a clinical trial supply chain setup, has lower gross margins compared to the rest of the product portfolio. So I think that it will take a couple of years post-launch until we are up and running, but we will definitely see improvements 12 months after the European launch. We will see improvements. And then going further into this. You need to keep in mind that the PMA in the United States and a class III device here in Europe involve complex regulatory processes. There are quite long regulatory timelines for all production and product improvement projects. So I would say we need probably a couple of years to get up to both scale and optimize production before we see the really high margins we see on more mature products.

Elvin Roleder
59:56 - 60:36

Okay. Great. Thank you. And just one more from me, looking at cash R&D costs here in the quarter. It took quite a noticeable step up in Q2 versus Q1. And I guess also versus Q2 last year. I appreciate that. I acknowledge, of course, that you have the kind of intensive work with both the PMA submission and the European approval. But are there any extra temporary effects that are specific to Q2 now that will start to abate once we have a potential approval in Europe? Or how should we look at R&D when we include capitalized development as well?

Kristoffer Nordström
60:37 - 61:38

I am glad you asked that question. It has been a busy quarter. We have talked about our high focus on our regulatory processes, primarily in the US. So naturally, the CAPEX and the R&D spend in Q2 was higher. We will see that go down in the second half of the year. And especially as we what will happen is that when we get the CE marking, we will start to amortize the CapEx tied to the CE marking. So to say. I've disclosed that before and it is around 25 million SEK per year in amortization. But despite this, we still believe that we should be able to end the year. If we track sales-wise, we should be able to end the year. Being cash positive for 2026 would be the first time in its history.

Elvin Roleder
61:42 - 61:48

Okay, great. Thank you so much for taking my questions in the nick of time. I will get out of the queue. Thank you.

Christoffer Rosenblad
61:49 - 62:14

Thank you so much. And with that, I want to conclude this quarterly Q2 report. And I hope to see you all back on October 22nd for the Q3 report as well. But thank you very much for the good questions, and thank you, everyone, for listening and being part of the journey of making sure that nobody dies waiting for an organ.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…